NO790647L - PROCEDURE FOR THE PREPARATION OF 2-METHOXYBENZAMIDES - Google Patents

PROCEDURE FOR THE PREPARATION OF 2-METHOXYBENZAMIDES

Info

Publication number
NO790647L
NO790647L NO790647A NO790647A NO790647L NO 790647 L NO790647 L NO 790647L NO 790647 A NO790647 A NO 790647A NO 790647 A NO790647 A NO 790647A NO 790647 L NO790647 L NO 790647L
Authority
NO
Norway
Prior art keywords
mol
water
mixture
ether
methoxy
Prior art date
Application number
NO790647A
Other languages
Norwegian (no)
Inventor
Henry Najer
Jean Pierre Kaplan
Daniel Charles Leon Obitz
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7805579A external-priority patent/FR2418225A1/en
Application filed by Synthelabo filed Critical Synthelabo
Publication of NO790647L publication Critical patent/NO790647L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Description

Fremgangsmåte for fremstilling av 2-metoksybenzamider. Process for the production of 2-methoxybenzamides.

Foreliggende oppfinnelse vedrorer en fremgangsmåte for fremstilling av 2-metoksybenzamider, i form av racemater eller enantiomerer, med den generelle formel (I) The present invention relates to a process for the production of 2-methoxybenzamides, in the form of racemates or enantiomers, with the general formula (I)

hvori in which

n er 1, 2, 3 eller 4,n is 1, 2, 3 or 4,

R er et radikal SC^NR^R^ hvori og R2uavhengig av hverandre står for hydrogen eller alkyl, eller et radikal S(°)mR3hvori R^er alkyl og m er 0, 1 eller 2, eller halogen, eller CF^, idet alkylgruppene har 1 til 4 karbonatomer, R is a radical SC^NR^R^ in which and R2 independently of each other stand for hydrogen or alkyl, or a radical S(°)mR3 in which R^ is alkyl and m is 0, 1 or 2, or halogen, or CF^, as the alkyl groups have 1 to 4 carbon atoms,

og addisjonssalter derav med farmasoytisk tålbare syrer,and addition salts thereof with pharmaceutically acceptable acids,

og det særegne ved fremgangsmåten i henhold til oppfinnelsen er at et pyrrolidin, enten racemisk eller optisk aktivt, med den generelle formel (III) and the distinctive feature of the method according to the invention is that a pyrrolidine, either racemic or optically active, with the general formula (III)

hvori n har den ovennevnte betydning, omsettes med en benzosyre eller et funksjonelt derivat derav, halogenid eller alkylester, med formel (II) in which n has the above meaning, is reacted with a benzoic acid or a functional derivative thereof, halide or alkyl ester, of formula (II)

hvori R har den ovennevnte betydning, wherein R has the above meaning,

og erholdte forbindelser med formel (I) overfores eventuelt i sine syreaddisjonssalter. and obtained compounds of formula (I) are optionally transferred into their acid addition salts.

Pyrrolidinene (III) oppnås på klassisk måte ved å gå ut fra ^-butyrolakton eller tf-klor-butylklorid som omsettes med et amin The pyrrolidines (III) are obtained in the classical way by starting from ^-butyrolactone or t-chlorobutyl chloride which is reacted with an amine

hvori n har den ovennevnte betydning, hvoretter det oppnådde l-cykloalkyl-2-okso-yrrolidin omdannes til l-cykloalkyl-2-nitrometylen-pyrrolidin som hydrogeneres til 2-aminometyl-l-cyklo-alkyl-pyrrolidin. in which n has the above meaning, after which the obtained 1-cycloalkyl-2-oxo-pyrrolidine is converted to 1-cycloalkyl-2-nitromethylene-pyrrolidine which is hydrogenated to 2-aminomethyl-1-cycloalkyl-pyrrolidine.

Kondensasjonsreaksj onen i "henhold til oppfinnelsen kan gjennomfores ved en temperatur fra 0 til 30°C. The condensation reaction according to the invention can be carried out at a temperature from 0 to 30°C.

De oppnådde forbindelser har en innvirkning på sentralnervesystemet. The compounds obtained have an impact on the central nervous system.

De etterfolgende eksempler illustrerer oppfinnelsen.The following examples illustrate the invention.

Analyser og spektra IR og RMN bekrefter strukturen av forbindelsene. . Eksempel 1 N-/0.-cyklopropyl-2-pyrrolidinyl) -mety 17-2-metoksy-5-sulfamoyl-benzamid og dets metansulfonat 1. 3- cyklopropylaminokarbonyl- propylklorid. Analyzes and spectra IR and RMN confirm the structure of the compounds. . Example 1 N-((O.-cyclopropyl-2-pyrrolidinyl)-methyl 17-2-methoxy-5-sulfamoyl-benzamide and its methanesulfonate 1.3-cyclopropylaminocarbonyl-propyl chloride.

I en 2 liters reaktor anbringes 57,1 g (1 mol) destillert cyklopropylamin, 101,2 g (1 mol) trietylamin og 750 ml torr eter. Det avkjoles på et saltblandet isbad ved omtrent -10°C og innfores dråpevis sakte en opplosning av 112 ml (=141 g:l mol) y~klorbutyrylklorid i 150 ml eter idet det sikres at temperaturen ikke overstiger -5°C. Denne tilsetning krever flere timer. Reaksjonsblandingen tillates å bli varmere og settes bort over natten. Det tilsettes 500 ml vann og kloroform i tilstrekkelig mengde for at alt faststoff forsvinner hvoretter det omrores og det vandige fase dekanteres. Den organiske fase vaskes med surt vann og deretter med bikarbonatholdig vann og til slutt med vann og torkes over magnesiumsulfat. Uorganiske bestanddeler frafiltreres og filtratet inndampes til torrhet. Det oppnås et hvitt faststoff. 57.1 g (1 mol) of distilled cyclopropylamine, 101.2 g (1 mol) of triethylamine and 750 ml of dry ether are placed in a 2 liter reactor. It is cooled in a salt-mixed ice bath at approximately -10°C and a solution of 112 ml (=141 g:l mol) y~chlorobutyryl chloride in 150 ml of ether is slowly introduced dropwise, ensuring that the temperature does not exceed -5°C. This addition requires several hours. The reaction mixture is allowed to warm and is set aside overnight. 500 ml of water and chloroform are added in a sufficient amount so that all solids disappear, after which it is stirred and the aqueous phase is decanted. The organic phase is washed with acidic water and then with bicarbonate-containing water and finally with water and dried over magnesium sulfate. Inorganic components are filtered off and the filtrate is evaporated to dryness. A white solid is obtained.

Dette omkrystalliseres fra omtrent 350 ml isopropyleter. This is recrystallized from about 350 ml of isopropyl ether.

Smp.T=69,5 - 71°C.Mp.T=69.5 - 71°C.

2. l- cyklopropyl- 2- okso- pyrrolidin.2. 1-cyclopropyl-2-oxo-pyrrolidine.

I en 2 liters erlenmeyerkolbe anbringes 37 g (0,77 mol) natriumhydrid som vaskes fire ganger med petroleter og overdekkes med 1 1.torr DMSO. Det oppvarmes forsiktig til 50-60°C og oppnås gassutvikling som viser dannelse av dimsyl-ion. 37 g (0.77 mol) of sodium hydride are placed in a 2 liter Erlenmeyer flask, which is washed four times with petroleum ether and covered with 1 1 torr DMSO. It is heated carefully to 50-60°C and gas evolution is achieved which shows the formation of dimsyl ion.

Når.gassutviklingen er avsluttet avkjoles reaksjonsblandingen i isblandet vann og man innforer dråpevis tilstrekkelig hurtig en opplosning av 118,5 g (0,733 mol) av det foregående klorerte amid i 300 ml DMSO hvoretter blandingen settes bort over natten ved vanlig temperatur. Det omrores i 10 timer og blandingen settes bort ytterligere en natt. Blandingen uthelles deretter på.2 kg is, tilsettes salt til metning og ekstraheres med kloroform tre ganger. When the evolution of gas has ended, the reaction mixture is cooled in ice-cold water and a solution of 118.5 g (0.733 mol) of the preceding chlorinated amide in 300 ml of DMSO is introduced dropwise and sufficiently quickly, after which the mixture is left overnight at ordinary temperature. It is stirred for 10 hours and the mixture is set aside for a further night. The mixture is then poured onto 2 kg of ice, salt is added to saturation and extracted with chloroform three times.

Ekstraktens vaskes fire ganger med omtrent 120 ml vann ogThe extract is washed four times with approximately 120 ml of water and

deretter 2 ganger med saltholdig vann og torkes til slutt over magnesiumsulfat. Etter filtrering avdampes løsningsmiddel under vakuum og resten destilleres med en liten adiabatisk kolonne under redusert trykk. Etter to forlopsfraksjoner inneholdende hovedsakelig DMSO (Kp13: 75-112°C) oppnås produktet: Kp13= 112-114°C. then 2 times with saline water and finally dried over magnesium sulphate. After filtration, the solvent is evaporated under vacuum and the residue is distilled with a small adiabatic column under reduced pressure. After two preliminary fractions containing mainly DMSO (Kp13: 75-112°C), the product is obtained: Kp13= 112-114°C.

3. l- cyklopropyl- 2- nitrometylengpyrrolidin.3. 1-cyclopropyl-2-nitromethylene pyrrolidine.

I en 500 ml erlenmeyerkolbe anbringes 35,05 g (0,28 mol) av det foregående laktam og 35,32 g (0,28 mol) dimetylsulfat hvoretter blandingen oppvarmes ved 60°C i 4 timer. Det avkjoles på is og tilsettes dråpevis en losning av natriummetylat (fremstilt fra 6,44 g (0,28 gat) natrium i 80 ml metanol) hvoretter det oppvarmes ved 50°C i ^ time. Man avkjoles på nytt til 0°C og tilsetter dråpevis 25,64 g (0,42 mol) nitrométan. Blandingen settes bort i 12 timer ved vanlig temperatur og oppvarmes ved 50°C i 5 timer. Blandingen settes på nytt bort over natten. Metanol avdampes til torrhet og resten opptas mellom kloroform og vann, omrystes, dekanteres og den vandige fase ekstraheres på nytt to ganger med kloroform. Kloroformekstraktene vaskes med vann og torkes deretter over magnesiumsulfat, filtreres og inndampes til torrhet. Det oppnås et gult fast stoff som er litt gummiaktig og som opptas i isopropyleter, omrores, In a 500 ml Erlenmeyer flask, 35.05 g (0.28 mol) of the preceding lactam and 35.32 g (0.28 mol) dimethyl sulfate are placed, after which the mixture is heated at 60° C. for 4 hours. It is cooled on ice and a solution of sodium methylate (prepared from 6.44 g (0.28 gat) of sodium in 80 ml of methanol) is added dropwise, after which it is heated at 50°C for ½ hour. It is cooled again to 0°C and 25.64 g (0.42 mol) nitromethane is added dropwise. The mixture is set aside for 12 hours at ordinary temperature and heated at 50°C for 5 hours. The mixture is again put away overnight. Methanol is evaporated to dryness and the residue is taken up between chloroform and water, shaken, decanted and the aqueous phase is extracted again twice with chloroform. The chloroform extracts are washed with water and then dried over magnesium sulphate, filtered and evaporated to dryness. A slightly gummy yellow solid is obtained which is taken up in isopropyl ether, stirred,

avkjoles og avsuges på filter hvorved det oppnås gule krystaller. cooled and suctioned off on a filter whereby yellow crystals are obtained.

Disse omkrystalliseres fra isopropyleter med en liten mengde isopropylalkohol i varmen, avkjoles og et gult faststoff oppnås. These are recrystallized from isopropyl ether with a small amount of isopropyl alcohol in the heat, cooled and a yellow solid is obtained.

Smp.T= 115,5 - 116,5°C. Mp.T= 115.5 - 116.5°C.

4. l- cyklopropyl- 2- aminometyl- pyrrolidin.4. 1-cyclopropyl-2-aminomethyl-pyrrolidine.

I et hydrogeneringsapparat anbringes 18,5 g (0,11 mol) av det foregående pyrrolidin, metanol og raney-nikkel hvoretter det innfores hydrogen under vanlig trykk ved omgivelsenes temperatur. Tilstrekkelig hurtig tilfores 9,5 1 hydrogen hvoretter absorbsjonen avbrytes. Blandingen omrores i 1 time hvoretter katalysatoren frafiltreres, renses med metanol flere ganger og filtratene inndampes til torrhet. Det oppnås en rodbrun olje som destilleres under redusert trykk. Det oppnås en ufarvet olje. 18.5 g (0.11 mol) of the preceding pyrrolidine, methanol and Raney nickel are placed in a hydrogenation apparatus, after which hydrogen is introduced under normal pressure at ambient temperature. Sufficiently quickly, 9.5 1 of hydrogen are supplied, after which the absorption is interrupted. The mixture is stirred for 1 hour, after which the catalyst is filtered off, cleaned with methanol several times and the filtrates are evaporated to dryness. A red-brown oil is obtained which is distilled under reduced pressure. A colorless oil is obtained.

nD<21>= 1,4825. Kp'l3= 78°c-5. N-/"(l-cyklopropyl-2-pyrrolidinyl )-metyl7-2-metoksy-5-sulfamoyl-benzamid. nD<21>= 1.4825. Kp'13 = 78°c-5. N-(1-cyclopropyl-2-pyrrolidinyl)-methyl-7-2-methoxy-5-sulfamoyl-benzamide.

I en 250 ml erlenmeyerkolbe anbringes 6,03 g (0,043 mol) av det ovennevnte pyrrolidin sammen med 5,95 g (0,043 mol) kaliumkarbonat i aceton (ca. 120 ml). Blandingen avkjoles til mellom 0 og 5°C og det tilsettes dråpevis en losning av 10,73 g In a 250 ml Erlenmeyer flask, place 6.03 g (0.043 mol) of the above-mentioned pyrrolidine together with 5.95 g (0.043 mol) of potassium carbonate in acetone (approx. 120 ml). The mixture is cooled to between 0 and 5°C and a solution of 10.73 g is added dropwise

(0,043 mol) av 2-metoksy-5-sulfamoyl-benzosyre i omtrent 100 ml aceton. Blandingen blir varmere og omrores i 2 timer ved 20°C. Aceton avdampes til torrhet (T<30°C) og den faste rest opptas mellom vann og eter, omrores og faststoffet avsuges på filter hvoretter det vaskes omhyggelig med vann og eter. Det oppnås et hvitbeige faststoff. (0.043 mol) of 2-methoxy-5-sulfamoyl-benzoic acid in about 100 ml of acetone. The mixture becomes warmer and is stirred for 2 hours at 20°C. Acetone is evaporated to dryness (T<30°C) and the solid residue is taken up between water and ether, stirred and the solid is sucked off on a filter after which it is washed carefully with water and ether. A white-beige solid is obtained.

Det omkrystalliseres fra en blanding metanol/etanol (50/50), filtreres noe vanskelig i varmen hvoretter det omkrystalliseres, avsuges på filter, vaskes og det hvite faststoff torkes. It is recrystallized from a mixture of methanol/ethanol (50/50), filtered somewhat difficult in the heat, after which it is recrystallized, suction filtered, washed and the white solid dried.

Smp.T= 172 - 172,5°C (spalting).Mp.T= 172 - 172.5°C (decomposition).

6. Metansulfonat.6. Methanesulfonate.

I litt metanol anbringes i suspensjon 5,3 g (0,015 mol) av den foregående base og det tilsettes 1,44 g (0,015 mol) metansulfonsyre. Alt loses. Losningsmidlet avdampes til torrhet og den gummiaktige rest opptas i kokende aceton og dette forer til krystallisering av et fint hvitt faststoff som omrores, avkjoles og avsuges på filter. Ved omkrystallisering fra etanol oppnås et fint hvitt pulver. 5.3 g (0.015 mol) of the preceding base are suspended in a little methanol and 1.44 g (0.015 mol) methanesulfonic acid is added. Everything is unloaded. The solvent is evaporated to dryness and the gummy residue is taken up in boiling acetone and this leads to the crystallization of a fine white solid which is stirred, cooled and filtered off. Upon recrystallization from ethanol, a fine white powder is obtained.

Smp.T = 178 - 180°C (spalting).Mp.T = 178 - 180°C (decomposition).

Eksempel 2 N-/Tl-cykloheksyl-2-pyrrolidinyl)-metyl7-2-metoksy-5-sulfamoyl-benzamid og dets metansulfonat. Example 2 N-((1-cyclohexyl-2-pyrrolidinyl)-methyl-7-2-methoxy-5-sulfamoyl-benzamide and its methanesulfonate.

1. l- cykloheksyl- 2- okso- pyrrolidin.1. 1-cyclohexyl-2-oxo-pyrrolidine.

I en 500 ml trykkbombe innfores 86,1 g (1 mol) ^-butyrolakton, 105 g (1,058 mol) cykloheksylamin og noen krystaller av hydrokinon. 86.1 g (1 mol) of β-butyrolactone, 105 g (1.058 mol) of cyclohexylamine and some crystals of hydroquinone are introduced into a 500 ml pressure bomb.

Det fores en nitrogenstrom gjennom roret og deretter lukkes dette, oppvarmes til 330°C i 10 timer, og det oppnås en olje som destilleres. Kokepunkt = 120°C (0,5 mmHg). A stream of nitrogen is fed through the rudder and then this is closed, heated to 330°C for 10 hours, and an oil is obtained which is distilled. Boiling point = 120°C (0.5 mmHg).

2. l- cykloheksyl- 2- nitrometylen- pyrrolidin.2. 1-cyclohexyl-2-nitromethylene-pyrrolidine.

I en 500 ml erlenmeyerkolbe innfores 66,9 g (0,4 mol) av det foregående laktam og 50,44 g (0,4 mol) metylsulfat. Det oppvarmes i 2 timer ved 60°C og avkjoles med et isbad og det innfores dråpevis natriummetylat fremstilt ved å gå ut fra 9,2 g 66.9 g (0.4 mol) of the preceding lactam and 50.44 g (0.4 mol) methyl sulfate are introduced into a 500 ml Erlenmeyer flask. It is heated for 2 hours at 60°C and cooled with an ice bath and sodium methylate prepared by starting from 9.2 g is introduced dropwise

(0,4 mol) Na. i 150 ml metanol. Det omrores i 1 time ved omgivelsenes temperatur hvoretter det avkjoles og tilsettes dråpevis 36,6 g (0,6 mol) nitrometan. I lopet av noen minutter utfelles et gult faststoff og omroringen fortsetter i 2 timer. (0.4 mol) of Na. in 150 ml of methanol. It is stirred for 1 hour at ambient temperature, after which it is cooled and 36.6 g (0.6 mol) of nitromethane are added dropwise. In the course of a few minutes, a yellow solid precipitates and stirring is continued for 2 hours.

Vann tilsettes hvoretter det gule faststoff frafiltreres, vaskes med vann og deretter med eter, det opploses i kloroform, torkes over magnesiumsulfat og inndampes. Det oppnås et faststoff som omkrystalliseres fra en blanding isopropyleter/etylacetat. Water is added, after which the yellow solid is filtered off, washed with water and then with ether, it is dissolved in chloroform, dried over magnesium sulphate and evaporated. A solid is obtained which is recrystallized from an isopropyl ether/ethyl acetate mixture.

Smp. = 14.9 - 149, 5°C. Temp. = 14.9 - 149.5°C.

3. l- cykloheksvl- 2- aminometvl- pvrrolidin.3. 1-cyclohexyl-2-aminomethyl-pyrrolidine.

Ved omgivelsenes temperatur og atmosfæretrykk hydrogeneres 21 gAt ambient temperature and atmospheric pressure, 21 g are hydrogenated

(0,1 mol) av den ovennevnte forbindelse med raney-nikkel som katalysator, i metanol. Etter at den teoretiske mengde hydrogen er absorbert frafiltreres katalysatoren og den alkoholiske losning inndampes. (0.1 mole) of the above compound with Raney nickel as catalyst, in methanol. After the theoretical amount of hydrogen has been absorbed, the catalyst is filtered off and the alcoholic solution is evaporated.

Det resterende olje destilleres.The remaining oil is distilled.

Kp.2Q= 142°C.Kp.2Q= 142°C.

4. N/"(l-cykloheksyl-2-pyrrolidinyl )-metyl/-2-metoksy-5-sulfamoyl- benzamid. 4. N/(1-Cyclohexyl-2-pyrrolidinyl)-methyl/-2-methoxy-5-sulfamoyl-benzamide.

I en erlenmeyerkolbe innfores 9 g (0,0493 mol) av aminet og 12,2 g . 9 g (0.0493 mol) of the amine and 12.2 g of .

(0,047 mol), av etylesteren av 2-metoksy-5-sulfamoyl-benzosyre og 50 ml vann. (0.047 mole), of the ethyl ester of 2-methoxy-5-sulfamoyl-benzoic acid and 50 ml of water.

Det oppvarmes under tilbakelop i 5 timer. Det avkjoles og blandingen utrives mellom vann og eter, og det hvite faststoff frafiltrerés og opploses i kloroform, torkes over magnesium- It is heated under reflux for 5 hours. It is cooled and the mixture is triturated between water and ether, and the white solid is filtered off and dissolved in chloroform, dried over magnesium

sulfat og oppløsningen inndampes. Det oppnås et faststoff som omkrystalliseres fra isopropanol. sulfate and the solution is evaporated. A solid is obtained which is recrystallized from isopropanol.

Smp. = 194 - 194,5°C. Temp. = 194 - 194.5°C.

5. Metansulfonat.5. Methanesulfonate.

I en rundkolbe innfores 11,1 g (0,028 mol) av basen i metanol og 2,69 g (0,028 mol) metansulfonsyre i metanol. 11.1 g (0.028 mol) of the base in methanol and 2.69 g (0.028 mol) of methanesulfonic acid in methanol are introduced into a round flask.

Det inndampes til torrhet og den resterende olje behandles med isopropylalkohol. It is evaporated to dryness and the remaining oil is treated with isopropyl alcohol.

Saltet krystalliserer og frafiltreres og omkrystalliseres fraThe salt crystallizes and is filtered off and recrystallized from

en blanding etylalkohol/metylalkohol.a mixture of ethyl alcohol/methyl alcohol.

Smp. = 196 - 197°C. Temp. = 196 - 197°C.

Eksempel 3 N-/"(l-cyklopropyl-2-pyrrolidinyl )-mety^J7-2-metoksy-5-metyltio-benzamid og dets hydroklorid. Example 3 N-[(1-cyclopropyl-2-pyrrolidinyl)-methyl]-2-methoxy-5-methylthiobenzamide and its hydrochloride.

/n= 1, m= 0, R3 = CH^//n= 1, m= 0, R3 = CH^/

1 en slipt erlenmeyerkolbe, avkjolt på isbad og anbragt under en r hitrogenstrom, innfores 6,6 g (0,047 mol) N-/"(l-cyklopropyl-2-pyrrol.idinyl)-metyl/amin og 6,5 g (0,047 mol) kaliumkarbonat i 100 ml aceton. Blandingen avkjoles til 1-2°C og tilfores dråpevis en losning av 10,2 g (0,047 mol) 2-metoksy-5-metyltié-benzoylklorid i aceton. Blandingen settes bort i 2 timer ved vanlig temperatur, losningsmidlet avdampes til torrhet og resten opptas i vann og kloroform.• Den organiske fase separeres, vaskes med vann og torkes over magnesiumsulfat. Etter filtrering og destillasjon opptas den viskose rest i eter, behandles med aktivt karbon og filtreres gjennom "Hyflo-supercel" for å fjerne en harpiksaktig gummi. 6.6 g (0.047 mol) of N-(1-cyclopropyl-2-pyrroleidinyl)-methylamine and 6.5 g (0.047 mol) of potassium carbonate in 100 ml of acetone. The mixture is cooled to 1-2°C and a solution of 10.2 g (0.047 mol) of 2-methoxy-5-methylthié-benzoyl chloride in acetone is added dropwise. The mixture is set aside for 2 hours at normal temperature, the solvent is evaporated to dryness and the residue is taken up in water and chloroform.• The organic phase is separated, washed with water and dried over magnesium sulfate. After filtration and distillation, the viscous residue is taken up in ether, treated with activated carbon and filtered through "Hyflo-supercell " to remove a resinous gum.

Etter avdamping av losningsmidlet blir det tilbake en blekgul olje som elueres over en torket kolonne med aluminiumoksyd (1700 g, TSC) ved hjelp av kloroform. Ved fraksjonering oppnås en blekgul olje som gir en enhetlig kromatografisk prove After evaporation of the solvent, a pale yellow oil remains which is eluted over a dried column of alumina (1700 g, TSC) using chloroform. Fractionation yields a pale yellow oil which gives a uniform chromatographic sample

(siiisiumoksyd-aceton og aluminiumoksyd-kloroform) og som spaltes, hvis man prover å destillere den. (silica-acetone and aluminum oxide-chloroform) and which splits if you try to distill it.

Denne olje omdannes til hydroklorid ved reaksjon mellom basen og saltsyre i eter. Hydrokloridet av n-/ll-cyklopropyl-2-pyrrolidinyl)-mdyi7-2-metoksy-5-metyltio-benzamid smelter ved 165 - 166°C. This oil is converted into hydrochloride by reaction between the base and hydrochloric acid in ether. The hydrochloride of n-(11-cyclopropyl-2-pyrrolidinyl)-mdyyl-2-methoxy-5-methylthiobenzamide melts at 165-166°C.

Eksempel 4 N-/ll-cyklopentyl-2-pyirolidinyl) -metyl/*- 5-me tyl ti o-2-metoksy-benzamid og dets hydroklorid. Example 4 N-(11-Cyclopentyl-2-pyrirolidinyl)-methyl (*-5-methyl thio-2-methoxy-benzamide and its hydrochloride).

/n=3, m=0, R3=C2H&7/n=3, m=0, R3=C2H&7

I en erlenmeyerkolbe, avkjolt på isbad og anbragt under nitrogenstrom, innfores 5,84 g (0,0346 mol) N-/"(l-cyklopentyl-2-pyrrolidinyD-metyl,/amin og 4,8 g (0,0346 mol) kaliumkarbonat i aceton. Det tilsettes dråpevis til denne blanding 8 g (0,0346 mol) 5-etyltio-2-metoksy-benzoyl i aceton. Kolben får anta omgivelsenes temperatur og omrores i 2 timer. In an Erlenmeyer flask, cooled in an ice bath and placed under a stream of nitrogen, introduce 5.84 g (0.0346 mol) N-/"(1-cyclopentyl-2-pyrrolidinyD-methyl,/amine and 4.8 g (0.0346 mol ) potassium carbonate in acetone. To this mixture is added dropwise 8 g (0.0346 mol) of 5-ethylthio-2-methoxy-benzoyl in acetone. The flask is allowed to assume ambient temperature and stirred for 2 hours.

Etter avdamping av losningsmidlet opptas resten i vann og eter, den organiske fase ekstraheres i surt miljo og gjores alkalisk og ekstraheres med eter. Etter torking over magnesiumsulfat avdampes eter og det oppnås en olje som renses ved å sendes gjennom en kolonne av silisiumoksyd ved eluering med aceton. After evaporation of the solvent, the residue is taken up in water and ether, the organic phase is extracted in an acidic environment and made alkaline and extracted with ether. After drying over magnesium sulfate, ether is evaporated and an oil is obtained which is purified by passing through a column of silicon oxide by elution with acetone.

Ved behandling av denne base med saltsyre i eter fremstilles N-/~(l-cyklopentyl-2-pyrrolidinyl)-metyl/-5-etyltio-2-metoksy-benzamid-hydroklorid som smelter ved 126,5 - 127,5°C. By treating this base with hydrochloric acid in ether, N-/~(1-cyclopentyl-2-pyrrolidinyl)-methyl/-5-ethylthio-2-methoxy-benzamide hydrochloride is produced which melts at 126.5 - 127.5°C .

Eksempel 5 N-/"(l-cyklopropyl-2-pyrrolidinyl )-metyl7-2-metoksy-5-metyl-sulfonyl-benxamid og dets hydroklorid. Example 5 N-(1-cyclopropyl-2-pyrrolidinyl)-methyl-7-2-methoxy-5-methyl-sulfonyl-benxamide and its hydrochloride.

/n=l, m=2, R3=CH37/n=1, m=2, R3=CH37

I en erlenmeyerkolbe opploses 5,33 g (0,038 mol) N-/Tl-cykloQ propyl-2-pyrrolidinyl)-metyi7amin i 100 ml vannfri aceton og tilsettes 5,25 g (0,038 mol) kaliumkarbonat. Denne suspensjon avkjoles ved omtrent 2°C og tilsettes dråpevis en losning av 9,45 g (0,038 mol) 2-metoksy-5-metyl-sulfonyl-benzoyl-klorid i 200 ml aceton, hele tiden under omroring. Isbadet fjernes og blandingen får anta vanlig temperatur i lopet av 2 timer under omroring. Losningsmidlet avdampes til torrhet og resten opptas i vann og kloroform. Den organiske fase vaskes med vann, deretter med saltholdig vann og torkes til slutt over magnesiumsulfat. In an Erlenmeyer flask, 5.33 g (0.038 mol) of N-((T1-cyclo(propyl-2-pyrrolidinyl)-methylamine) are dissolved in 100 ml of anhydrous acetone and 5.25 g (0.038 mol) of potassium carbonate are added. This suspension is cooled at approximately 2°C and a solution of 9.45 g (0.038 mol) of 2-methoxy-5-methyl-sulfonyl-benzoyl chloride in 200 ml of acetone is added dropwise, all the while stirring. The ice bath is removed and the mixture is allowed to reach normal temperature over the course of 2 hours while stirring. The solvent is evaporated to dryness and the residue is taken up in water and chloroform. The organic phase is washed with water, then with saline water and finally dried over magnesium sulphate.

Etter filtrering og avdamping av losningsmidlet blir tilbakeAfter filtration and evaporation the solvent remains

en brun olje som dekket under etylacetat omdannes til et rod-aktig faststoff som avsuges på filter, vaskes og torkes. a brown oil which is covered under ethyl acetate is converted into a root-like solid which is sucked off on a filter, washed and dried.

Smp. = 140 - 141°C. Temp. = 140 - 141°C.

Etter omkrystallisering fra isopropylalkohol er N-/"(l-cyklopropyl-2-pyrrolidinyl)-metyl7-2-metoksy-5-metylsulfonyl-benzamid et hvitt faststoff som smelter ved 140,5 - 141,5°C. After recrystallization from isopropyl alcohol, N-(1-cyclopropyl-2-pyrrolidinyl)-methyl7-2-methoxy-5-methylsulfonyl-benzamide is a white solid melting at 140.5 - 141.5°C.

Hydrokloridet, fremstilt ved reaksjon mellom ovennevnte base og saltsyre i aceton, metanol og etanol, smelter ved 165 - 166°C. The hydrochloride, prepared by reaction between the above-mentioned base and hydrochloric acid in acetone, methanol and ethanol, melts at 165 - 166°C.

I den etterfølgende tabell I er anfort forbindelse (I) fremstilt ved lignende metoder. In the following Table I, the indicated compound (I) is prepared by similar methods.

Enantiomerene av forbindelsene (I) oppnås enten ved spalting eller ved stereospesifikk syntese. De fremstilte forbindelser ble underkastet farmakologisk provning med hensyn til innvirkning på sentralnervesystemet. The enantiomers of the compounds (I) are obtained either by cleavage or by stereospecific synthesis. The compounds produced were subjected to pharmacological testing with regard to the effect on the central nervous system.

Akutt giftighet ble bestemt i hanmus, swiss CD1, med middelvekt 20 g, ved tilforsel i.p. Acute toxicity was determined in male mice, swiss CD1, with an average weight of 20 g, by i.p.

Den nevroleptiske aktivitet ble bestemt ved antagonisme overfor "klatring" ("climbing", "redressement") innfort ved apomorfin i mus i henhold til artikkelen av Gouret C, J. Pharmacol. The neuroleptic activity was determined by antagonism to "climbing" ("climbing", "redressement") induced by apomorphine in mice according to the article by Gouret C, J. Pharmacol.

(Paris) 4, 341 (1973). (Paris) 4, 341 (1973).

LD 50 utgjor 60 til 1000 mg/kg tilfort i.p.LD 50 amounts to 60 to 1000 mg/kg administered i.p.

ED 50 ved klatreproven varierer fra 0,3 til 1 mg/kg ved tilforsel i.p. og er 0,5 mg/kg, 0,6 mg/kg og 0,3 mg/kg for henholdsvis forbindelsene 4, 10 og 14. ED 50 in the climbing test varies from 0.3 to 1 mg/kg when administered i.p. and are 0.5 mg/kg, 0.6 mg/kg and 0.3 mg/kg for compounds 4, 10 and 14, respectively.

Forbindelsene kan anvendes for behandling av forskjellige psykosymatiske forstyrrelser og psykiske lidelser (depressive tilstander og psykoser). The compounds can be used for the treatment of various psychosymatic disorders and mental disorders (depressive states and psychoses).

Forbindelsene kan anvendes som sådanne eller i form av deres salter som aktive bestanddeler i forbindelse med alle vanlige tilsetningsmidler for oral, endorektal eller parenteral tilforsel. The compounds can be used as such or in the form of their salts as active ingredients in connection with all common additives for oral, endorectal or parenteral administration.

Total daglig dose kan utgjore 5 til 300 mg. Total daily dose can amount to 5 to 300 mg.

Claims (1)

Fremgangsmåte for fremstilling av terapeutisk aktive 2-metoksybenzamider, i form av racemater eller enantiomerer med den generelle formel (I) Process for the preparation of therapeutically active 2-methoxybenzamides, in the form of racemates or enantiomers with the general formula (I) hvori n er 1, 2, 3 eller 4, R er et radikal SC^ NR- j^ hvori R.^ og R2 uavhengig av hverandre står for hydrogen eller alkyl eller et radikal S(0)m R^ hvori R^ er alkyl og m er 0, 1 eller 2, eller halogen, eller CF^, idet alkylgruppene har 1 til 4 karbonatomer, såvel som deres addisjonssalter med farmasoytisk tålbare syrer, karakterisert ved at en syre eller et funksjonelt derivat derav med formel (II) in which n is 1, 2, 3 or 4, R is a radical SC^ NR- j^ in which R.^ and R2 independently of each other stand for hydrogen or alkyl or a radical S(0)m R^ in which R^ is alkyl and m is 0, 1 or 2, or halogen , or CF^, wherein the alkyl groups have 1 to 4 carbon atoms, as well as their addition salts with pharmaceutically acceptable acids, characterized in that an acid or a functional derivative thereof of formula (II) hvori R har den ovennevnte betydning, kondenseres med et pyrrolidin, i form av racemat eller enantiomer, med den generelle formel (III) wherein R has the above meaning, is condensed with et pyrrolidine, in the form of racemate or enantiomer, with it general formula (III) hvori n har den ovennevnte betydning.wherein n has the above meaning.
NO790647A 1978-02-27 1979-02-26 PROCEDURE FOR THE PREPARATION OF 2-METHOXYBENZAMIDES NO790647L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7805579A FR2418225A1 (en) 1978-02-27 1978-02-27 N-1-Cycloalkyl-2-pyrrolidinyl-methyl 2-methoxy-benzamide derivs. - for treating psychoses and depressive states, prepd. by reaction of 1-cycloalkyl-2-aminomethyl-pyrrolidine with methoxy-benzoic acid deriv.
FR7900259A FR2445829A2 (en) 1978-02-27 1979-01-05 METHOXY-2 BENZAMIDES AND THEIR THERAPEUTIC APPLICATION

Publications (1)

Publication Number Publication Date
NO790647L true NO790647L (en) 1979-08-28

Family

ID=26220462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO790647A NO790647L (en) 1978-02-27 1979-02-26 PROCEDURE FOR THE PREPARATION OF 2-METHOXYBENZAMIDES

Country Status (18)

Country Link
JP (1) JPS54135765A (en)
AU (1) AU521027B2 (en)
BE (1) BE874489A (en)
DE (1) DE2907378A1 (en)
DK (1) DK82179A (en)
ES (1) ES478072A1 (en)
FI (1) FI790657A (en)
FR (1) FR2445829A2 (en)
GB (1) GB2016467A (en)
GR (1) GR66972B (en)
IL (1) IL56738A0 (en)
IT (1) IT1113417B (en)
LU (1) LU80975A1 (en)
NL (1) NL7901473A (en)
NO (1) NO790647L (en)
NZ (1) NZ189770A (en)
PT (1) PT69289A (en)
SE (1) SE7901707L (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0320630A1 (en) * 1987-11-19 1989-06-21 The Vanderbilt University Enantiometric iodobenzamides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH584688A5 (en) * 1972-06-23 1977-02-15 Delmar Chem
FR2294698A1 (en) * 1974-12-18 1976-07-16 Synthelabo NEW DERIVATIVES OF 2-METHOXY BENZAMIDES SUBSTITUTE, THEIR SALTS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM
FR2393794A2 (en) * 1977-06-06 1979-01-05 Synthelabo Therapeutic 2-methoxy benzamido methyl heterocycle(s) prepn. - from 2-methoxy benzoic ester(s) and amino methyl heterocycle(s)
JPS52106863A (en) * 1976-03-03 1977-09-07 Teikoku Hormone Mfg Co Ltd Synthesis of substituted benzamides
FR2360572A1 (en) * 1976-08-05 1978-03-03 Synthelabo Optically active (2)-amino-methyl-(1)-substd. pyrrolidine derivs. - intermediates for benzoylamino-methyl-pyrrolidine pharmaceuticals
JPS5365875A (en) * 1976-11-24 1978-06-12 Teijin Ltd Preparation of benzenesulfone amide derivs.

Also Published As

Publication number Publication date
ES478072A1 (en) 1979-07-01
FI790657A (en) 1979-08-28
AU4460379A (en) 1979-09-06
IL56738A0 (en) 1979-05-31
IT1113417B (en) 1986-01-20
AU521027B2 (en) 1982-03-11
SE7901707L (en) 1979-08-28
PT69289A (en) 1979-03-01
FR2445829A2 (en) 1980-08-01
JPS54135765A (en) 1979-10-22
GB2016467A (en) 1979-09-26
LU80975A1 (en) 1980-09-24
NZ189770A (en) 1980-11-14
FR2445829B2 (en) 1982-09-10
NL7901473A (en) 1979-08-29
BE874489A (en) 1979-08-27
DE2907378A1 (en) 1979-09-06
DK82179A (en) 1979-08-28
IT7920541A0 (en) 1979-02-26
GR66972B (en) 1981-05-15

Similar Documents

Publication Publication Date Title
US6410582B1 (en) Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
US4301163A (en) Amino-ether oxides and use thereof in therapy
FR2558162A1 (en) NOVEL XANTHIN DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
DK162222B (en) 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
CA2114712A1 (en) Substituted phenyl sulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity
IE911683A1 (en) &#34;New aminopiperidine, aminopyrrolidine and aminoperhydroazepine compounds processes for the preparation thereof and pharmaceutical compositions containing them&#34;
DK158346B (en) METHOD OF ANALOGY FOR THE PREPARATION OF 4-AMINO-5-ALKYL SULPHONYL-O-ANISAMIDE DERIVATIVES AND 2-METHOXY-4-AMINO-5-ALKYLSULPHONYL BENZOIC ACIDS FOR USE AS INTERMEDIATRIC FRUIT SODANE FRUIT ACRODUCED FRUIT SODANE FRACTIONS THROUGH ANIMAL SUCCESS
NO338104B1 (en) Tetrahydroisoquinoline-sulfonamide derivatives, pharmaceutical compositions containing them and their use as therapeutic agents
US5001134A (en) Piperidines, processes of preparation and medications containing them
AU593605B2 (en) New dihydrobenzofuran- and chroman-carboxamide derivatives, processes for the preparation thereof and use thereof as neuroleptics
DE69019293T2 (en) Naphthyloxazolidone derivatives.
IE882179L (en) N,n-disubstituted arylamides
NO852133L (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PYRROLIDINON DERIVATIVES.
NO158739B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2-PIPERAZINOPYRIMIDINE DERIVATIVES.
DE69410359T2 (en) Benzospiroalkene derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0326106B1 (en) Alkylene diamines
FI67544C (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL PROPERTIES OF IMMEDIATE INSULATION
DK166584B1 (en) SUBSTITUTED 4-BENZYL-1H-IMIDAZOLES, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US20050096347A1 (en) Beta3-Adrenoreceptor agonists, agonist compositions and methods of using
DK156718B (en) METHOD OF ANALOGUE FOR PREPARING SUBSTITUTED 2-PHENYL-2- (PYRIDYLOXY, PYRIDYLAMINO OR PYRIDYLTHIO) -ETHYLAMINES OR ACID ADDITION SALTS THEREOF
US4868190A (en) N-pyridinyl-9H-carbazol-9-amines
US4208420A (en) New benzo [d] thiazole derivatives, process for their preparation and their therapeutic applications
KR20030024919A (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
BG62349B2 (en) N-substituted derivatives of 3-azabicyclo [3.2.0] heptane as neuroleptics
NO790647L (en) PROCEDURE FOR THE PREPARATION OF 2-METHOXYBENZAMIDES